人 CD33 抗体对
01AB03240
CD33 molecule (CD33) is a type I transmembrane sialic-acid-binding immunoglobulin-like lectin primarily expressed on myeloid lineage cells, including monocytes, macrophages, and granulocyte precursors. Upon binding to sialylated ligands, CD33 recruits SHP-1 and SHP-2 phosphatases via its cytoplasmic ITIM motifs, delivering inhibitory signals that dampen cytokine production and maintain immune cells in a resting state. Pathologically, CD33 is highly expressed on the blasts of approximately 90% of patients with acute myeloid leukemia (AML), making it a primary target for immunotherapies such as gemtuzumab ozogamicin. Additionally, CD33 variants are associated with altered microglial function and increased risk in Alzheimer’s disease.
| 规格 | 起售价 |
|---|---|
| 登录后可查看 | |
技术参数
- 靶点基因名
- CD33
- 基因别名
- SIGLEC3
- 蛋白别名
- CD33 molecule; CD33
- UniProt
- P20138
- 物种
- Human
产品详情
- 靶点名称
- CD33
- 蛋白名称
- CD33 molecule
- 蛋白别名
- Myeloid cell surface antigen CD33; Sialic acid-binding Ig-like lectin 3; Siglec-3; gp67; CD antigen CD33
- 靶点基因名
- CD33
- 基因别名
- SIGLEC3
- UniProt
- P20138
- 来源物种
- Homo sapiens (Human)
- 物种反应性
- Human
背景介绍
CD33 molecule (CD33) is a type I transmembrane sialic-acid-binding immunoglobulin-like lectin primarily expressed on myeloid lineage cells, including monocytes, macrophages, and granulocyte precursors. Upon binding to sialylated ligands, CD33 recruits SHP-1 and SHP-2 phosphatases via its cytoplasmic ITIM motifs, delivering inhibitory signals that dampen cytokine production and maintain immune cells in a resting state. Pathologically, CD33 is highly expressed on the blasts of approximately 90% of patients with acute myeloid leukemia (AML), making it a primary target for immunotherapies such as gemtuzumab ozogamicin. Additionally, CD33 variants are associated with altered microglial function and increased risk in Alzheimer’s disease.